相关实验视频
Updated: Jul 23, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
一种用于治疗住院患者COVID-19葡萄糖皮质醇诱导高血糖症的新型算法
Alexander B Karol1, Natalia Viera2, Selassie J Ogyaadu2
1Icahn School of Medicine at Mount Sinai, New York, NY.
概括
一个新的胰岛素协议用于管理COVID-19患者住院患者的葡萄糖皮质体诱导高血糖症,减少了低血糖事件. 这种方法提高了患者的安全性,而不会增加胰岛素使用或高血糖.
科学领域:
- 内分泌学 在内分泌学.
- 传染性疾病 传染性疾病
- 医院 医院 医疗 医疗 医疗 医疗
背景情况:
- 高血糖是2019年冠状病毒病 (COVID-19) 的住院患者的重大并发症,与更糟糕的结果相关.
- 常用于COVID-19治疗的葡萄糖皮质类药物可以诱导高血糖症,使患者管理复杂化.
- 在改善COVID-19患者的发病率和死亡率方面,有效管理葡萄糖皮质类药物诱导的高血糖是至关重要的.
研究的目的:
- 引入和评估一种新型的胰岛素定位方案,用于治疗住院COVID-19患者的葡萄糖皮质体诱导高血糖症.
- 评估该方案对低血糖事件,高血糖控制和胰岛素利用的影响.
- 在现实临床环境中确定新方案的安全性和有效性.
主要方法:
- 一项回顾性分析比较了65名COVID-19患者和在新的胰岛素定位协议下管理的葡萄糖皮质激素诱导高血糖症,与协议实施前入院的匹配队列进行了对比.
- 根据相关的临床特征,患者与1:1匹配.
- 收集和分析了低血糖事件,高血糖水平和胰岛素需求的数据.
主要成果:
- 新的胰岛素定位方案导致低血糖事件显著减少.
- 该协议没有导致高血糖症的增加.
- 在协议组和协议前组之间,胰岛素的利用仍然可以比较.
结论:
- 实施的胰岛素定位协议在住院COVID-19患者的葡萄糖皮质醇诱导高血糖症的安全管理中是有效的.
- 这种新的方法可以降低低血糖的风险,而不会影响血糖控制或增加胰岛素剂量.
- 该协议提供了一项有价值的策略,以改善患者护理和这一脆弱人群的结果.
更多相关视频
相关概念视频
Hypoglycemia and Glucagon
305
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
305
Diabetes: Management and Pharmacotherapy
319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
Insulin: Dosing Regimen and Adverse Effects
213
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
213
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Overview of Carbohydrate Metabolism
1.2K
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
1.2K
COPD: Management Using Bronchodilators and Corticosteroids
249
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
249

